July 26, 2019 10:40 AM EDTUpdated 01:16 PM

EMA backs five medicines; Solid Bio raises $60M in private placement

Natalie Grover

Reporter

→ The European Medicines Agency on Friday recommended five new medicines for approval, including Bayer’s cancer drug Vitrakvi — the site-agnostic cancer drug was given …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

EMA backs five medicines; Solid Bio raises $60M in private placement

Natalie Grover

Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

From weeks to days: how Aizon Intelligent Agents transform pharma validation

EMA backs five med­i­cines; Sol­id Bio rais­es $60M in pri­vate place­ment

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

EMA backs five medicines; Solid Bio raises $60M in private placement